What one share of Exelixis holds
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S.
Exelixis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-03; the balance sheet is as of 2026-07-03.
| Sales | $9.01 |
|---|---|
| Profit | $3.18 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | $4.33 |
| Cash and investments | $5.56 |
| Book value | $7.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $1.42 | −$1.26 | $0.06 | −$0.19 | — | −$1.53 |
| 2010 | $1.71 | −$0.85 | $0.02 | −$0.95 | — | −$2.09 |
| 2011 | $2.22 | $0.58 | $0.01 | −$1.23 | — | $0.67 |
| 2012 | $0.30 | −$0.91 | $0.02 | −$0.79 | — | $1.30 |
| 2013 | $0.17 | −$1.29 | $0.01 | −$1.09 | — | $0.08 |
| 2014 | $0.13 | −$1.34 | $0.00 | −$1.21 | — | −$0.81 |
| 2015 | $0.18 | −$0.77 | $0.00 | −$0.68 | — | −$0.62 |
| 2016 | $0.76 | −$0.28 | $0.01 | $0.83 | — | $0.31 |
| 2017 | $1.45 | $0.49 | $0.07 | $0.46 | — | $0.96 |
| 2018 | $2.73 | $2.21 | $0.11 | $1.22 | — | $4.29 |
| 2019 | $3.07 | $1.02 | $0.04 | $1.63 | — | $5.53 |
| 2020 | $3.11 | $0.35 | $0.10 | $0.56 | — | $6.03 |
| 2021 | $4.45 | $0.72 | $0.17 | $1.08 | — | $6.93 |
| 2022 | $4.96 | $0.56 | $0.09 | $1.03 | — | $7.68 |
| 2023 | $5.69 | $0.65 | $0.13 | $0.91 | — | $7.48 |
| 2024 | $7.32 | $1.76 | $0.10 | $2.27 | — | $7.97 |
| 2025 | $8.23 | $2.78 | $0.03 | $3.11 | — | $8.23 |
Common questions about Exelixis
How much does one share of Exelixis earn?
Over the last 12 months, each share of Exelixis earned $3.18 of profit on $9.01 of sales, keeping about 35¢ of every $1 (profit margin).
Does Exelixis pay a dividend?
Exelixis didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Exelixis’s book value per share?
Exelixis’s book value is $7.41 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of July 3, 2026.
How much cash and debt does each share of Exelixis have?
Each share of Exelixis has $5.56 of cash and investments, as of July 3, 2026.
What is Exelixis’s free cash flow per share?
$4.33 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Exelixis bought back shares?
Exelixis’s share count rose about 163% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.